Pharmacy(BK4007),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4007 Pharmacy

Closed 12-08 16:00:00 EST

825.50

-5.25

-0.63%

High832.17	Low822.87	Vol569.04M
Open831.10	D1 Closing830.75	Amplitude1.12%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O18.10B	T/O Rate--	Tradable Shares0.00
P/B5.074901	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4007","market":"US","secType":"PLATE","nameCN":"Pharmacy","latestPrice":825.49634,"timestamp":1765227599999,"preClose":830.7454,"halted":0,"volume":569035766,"delay":0,"changeRate":-0.006319,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-5.249084,"latestTime":"12-08 16:00:00 EST","open":831.1011,"high":832.1694,"low":822.8695,"amount":18100594626.032333,"amplitude":0.011195,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765270800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.074901,"peRate":24.606297,"turnoverRate":0.012477,"increases":92,"decrements":92,"flats":6,"marketCap":3272302680286.0625,"floatMarketCap":3124846324532.0625},"requestUrl":"/m/hq/s/BK4007","defaultTab":"news","newsList":[{"id":"2590636776","title":"Review Preview: Fed Jitters -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2590636776","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590636776?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:55","pubTimestamp":1765241700,"startTime":"0","endTime":"0","summary":"Jerom-ino. Stocks stumbled on Monday, as investors had little to cling to before the Federal Reserve  takes the plunge with another interest rate cut. The Federal Open Market Committee meets over the next two days with an expected quarter-point cut due at 2 p.m. on Wednesday. The real question is what comes next.\"The December Federal Open Market Committee meeting seems likely to see a 'hawkish cut', if such a thing really exists,\" 22V Research's Peter Williams recently noted. On Monday he wrote that Fed Chair Jerome Powell faces a challenge in that \"there is very little consensus on the FOMC about the near-term outlook for policy. There is simply no way for Powell to avoid the disagreements, both formal dissents and the broader bevy of Fedspeak.\". While that news boosted their stocks, GLP-1 stalwarts Eli Lilly & Co. and Novo Nordisk took a hit. There has been concerns that their dominance could be upended, particularly by products that don't require repeated injections, given how fast ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1127390331.HKD","IE00B7KXQ091.USD","LU2491050154.USD","LU2168564222.USD","LU0122379950.USD","LU1323610961.USD","LU0198837287.USD","LU1023059063.AUD","LU2168564149.EUR","LU2237443622.USD","LU0203202063.USD","LU1291159041.SGD","NVO","SG9999001176.USD","LU0106261372.USD","LU2602419157.SGD","SG9999014906.USD","IE00BZ1G4Q59.USD","SG9999014914.USD","LU0266013472.USD","LU0353189680.USD","LU0823434583.USD","LU0823416689.USD","LU0094547139.USD","LU1548497426.USD","BK4533","LU2211815571.USD","IE00BKVL7J92.USD","LU2324357040.USD","IE0002141913.USD","LU0354030511.USD","SG9999015945.SGD","LU1988902786.USD","LU0786609619.USD","LU2471134952.CNY","LU0354030438.USD","LU0820561909.HKD","LU2168564065.EUR","LU0672654240.SGD","LU1061106388.HKD","IE00BFSS7M15.SGD","LU2471134523.USD","LU0238689110.USD","LU2265009873.SGD","LU1551013342.USD","IE0009355771.USD","LU0323591593.USD","LU0234572021.USD","LU2087625088.SGD","SG9999015986.USD","LU2237443895.HKD","LU0456855351.SGD","IE00BWXC8680.SGD","SG9999018857.SGD","LLY","LU2237443465.HKD","LU2462157665.USD","LU2468319806.SGD","LU1868837136.USD","LU2461242641.AUD","LU0353189763.USD","LU2552382132.HKD","LU2237443978.SGD","BK4534","LU1093756168.USD","TLTW","IE00BKDWB100.SGD","LU2089984988.USD","IE00B1XK9C88.USD","LU0006306889.USD","IE00B1BXHZ80.USD","LU1814569148.SGD","LU2112291526.USD","LU2236285917.USD","LU2360106947.USD","LU0289739699.SGD","LU2417539215.USD","LU2471134879.HKD","LU2746668461.USD","LU1551013425.SGD","IE00BK4W5L77.USD","LU0096364046.USD","GB00BDT5M118.USD","LU0820561818.USD","LU2237443549.SGD","LU0882574139.USD","SG9999001176.SGD","LU0114720955.EUR","SG9999013999.USD","LU2361045086.USD","LU2750360997.AUD","LU0097036916.USD","LU0109391861.USD","IE00BFSS8Q28.SGD","SGXZ31699556.SGD","LU1974910355.USD","SG9999018865.SGD","IE00B2B36J28.USD","LU2108987350.USD","LU1057294990.SGD","LU1868836914.USD","LU1868837300.USD","LU1917777945.USD","LU1280957306.USD","LU2357305700.SGD","SGXZ99366536.SGD","LU2237443382.USD","SG9999015978.USD","LU2063271972.USD","LU0640476718.USD","LU0882574055.USD","IE00BJLML261.HKD","LU1232071149.USD","LU2168564495.EUR","IE00BKPKM429.USD","LU0203201768.USD","LU1366192091.USD","LU2456880835.USD","LU2552382215.SGD","LU1093756325.SGD","LU0061475181.USD","BK4516","IE00BN29S564.USD","LU0943347566.SGD","IE0004445015.USD","BK4007","BK4585","IE00BJJMRY28.SGD","SGXZ81514606.USD","LU2361044949.HKD","LU0689472784.USD","LU2361044865.SGD","LU0058720904.USD","IE0004445239.USD","TMF","BK4588","LU0256863902.USD","LU0432979614.USD","BK4532","LU0320765992.SGD","LU2106854487.HKD","LU2264538146.SGD","SG9999014880.SGD","LU2491049909.HKD","LU2168563687.JPY","IE0005OL40V9.USD","SGXZ57979304.SGD","LU0320765059.SGD","LU2023250504.SGD","LU0466842654.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU2552382058.USD","SGXZ51526630.SGD","LU0708995401.HKD","LU0417517546.SGD","IE00B4JS1V06.HKD","LU0471298777.SGD","BK4599","LU1989771016.USD","LU1267930730.SGD","LU1069344957.HKD","LU1868836591.USD","LU0256863811.USD","LU0154236417.USD","LU2237438978.USD","BK4581","LU1720051108.HKD","LU2746668974.SGD","LU1868836757.USD","IE00BJJMRX11.SGD","SG9999014898.SGD","IE00B4R5TH58.HKD","LU2471134796.USD","SG9999017495.SGD","LU2750360641.GBP","LU2491050071.SGD","LU0823434740.USD","SG9999015952.SGD","LU1720051017.SGD","LU1712237335.SGD","LU1804176565.USD","LU1623119135.USD","LU0079474960.USD","LU1983299246.USD","IE00B775H168.HKD","LU0385154629.USD","LU1064131342.USD","LU0889565916.HKD","IE00BK4W5M84.HKD","LU1035775433.USD","IE00BJT1NW94.SGD","LU0471298694.HKD","LU0316494557.USD","LU0109394709.USD"],"gpt_icon":1},{"id":"1191255076","title":"Weight-Loss Drugs Enter \"Volume-for-Value\" Phase: Consumerization Trend Accelerates as Lower Prices Stimulate Massive Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1191255076","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191255076?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:53","pubTimestamp":1765241623,"startTime":"0","endTime":"0","summary":"The global weight-loss drug market is undergoing a profound transformation, with volume-for-value pricing and consumerization trends reshaping the competitive landscape. According to a December 8...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","SG9999002224.SGD","SG9999002232.USD","IE00BZ1G4Q59.USD","IE00BBT3K403.USD","NVO","LU0456855351.SGD","LU2237443382.USD","IE00B19Z3B42.SGD","LU0058720904.USD","LU1894683264.USD","LU0742534661.SGD","LU1894683348.USD","BK4592","IE000M9KFDE8.USD","LU1093756168.USD","BK4007","BK4533","LU0061475181.USD","LU0321505868.SGD","IE0002270589.USD","LU1868837300.USD","LU0251142724.SGD","SG9999001176.SGD","LU0122379950.USD","LU0154236417.USD","LU2471134796.USD","LU1791807156.HKD","BK4127","IE0004091025.USD","IE00BFXG1179.USD","BK4585","IE00BSNM7G36.USD","LU2471134952.CNY","LU2237438978.USD","BK4532","LLY","LU0289739699.SGD","LU0225284248.USD","LU1668664300.SGD","BK4568","IE00B19Z3581.USD","LU2471134523.USD","LU1883839398.USD","BK4516","LU2750360641.GBP","LU0306806265.USD","LU2750360997.AUD","SG9999013999.USD","LU0048573561.USD","LU2237443465.HKD","BK4588","SG9999011175.SGD","LU2471134879.HKD","SG9999003800.SGD","IE00BKVL7J92.USD","LU1023059063.AUD","LU1057294990.SGD","LU1868836591.USD","LU1868836914.USD","LU1066053197.SGD","LU0985481810.HKD","BK4581","LU1868836757.USD","LU1804176565.USD","LU2265009873.SGD","LU1093756325.SGD","IE0034235188.USD","BK4552","LU0170899867.USD","BK4504","LU0234572021.USD","LU2237443895.HKD","LU0345770308.USD","LU2237443622.USD","LU1066051498.USD","LU2237443978.SGD","IE0004086264.USD","SGXZ57979304.SGD","IE00BLSP4239.USD","LU0321505439.SGD","LU0096364046.USD","LU0251131958.USD","LU0868494617.USD","BK4599","LU0225771236.USD","PFE","LU2237443549.SGD","BK4534","IE00BLSP4452.SGD","BK4550","SG9999001176.USD","LU0306807586.USD","LU1868837136.USD","LU0345770993.USD"],"gpt_icon":1},{"id":"2590364342","title":"BUZZ-Fulcrum Therapeutics dips after unveiling $150 million share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2590364342","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590364342?lang=en_us&edition=fundamental","pubTime":"2025-12-09 07:29","pubTimestamp":1765236598,"startTime":"0","endTime":"0","summary":"BUZZ-Fulcrum Therapeutics dips after unveiling $150 million share sale** Shares of drug developer Fulcrum Therapeutics FULC.O fall 1.8% to $12.75 in extended trading** FULC kicks off public offering of $150 million worth of shares** Stock closed 46% higher on Monday after FULC unveiled trial data of blood disorder drug** J.P. Morgan, Leerink Partners, and Cantor are book-running managers for offering** Proceeds will be used for general purposes, including research and development and to fund clinical trials, among other purposes** 7 of 9 brokerages rate the stock \"buy\" or higher, one \"hold\" and one \"sell\"; median PT $20 - data compiled by LSEG** As of last close, FULC up 176.4% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE14L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","FULC","MNSH","BK4007"],"gpt_icon":0},{"id":"2590836141","title":"Press Release: Trulieve Announces US$100 Million Private Placement of 10.5% Senior Secured Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2590836141","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590836141?lang=en_us&edition=fundamental","pubTime":"2025-12-09 07:00","pubTimestamp":1765234800,"startTime":"0","endTime":"0","summary":"TALLAHASSEE, Fla., Dec. 8, 2025 /PRNewswire/ -- Trulieve Cannabis Corp.   , a leading and top-performing cannabis company in the U.S., today announced that it has received commitments for a private placement of 10.5% Senior Secured Notes due 2030  for aggregate gross proceeds of US$100.0 million . The Notes, which will be issued at 100% of face value, will be senior secured obligations of the Company. The Notes will bear interest at a rate of 10.5% per annum, payable semi-annually in equal installments until the maturity date, unless earlier redeemed or repurchased. The Notes will mature on or about December 17, 2030, and may be redeemed in whole or in part, at any time from time to time, on or after the date that is two years following the issue date at the applicable redemption price set forth in the supplemental indenture to be entered into on closing of the Offering.The Company intends to use the net proceeds of the Offering for capital expenditures and other general corporate purp","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TCNNF","BK4007"],"gpt_icon":0},{"id":"2590369042","title":"Perrigo Co. PLC Stock Underperforms Monday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590369042","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590369042?lang=en_us&edition=fundamental","pubTime":"2025-12-09 06:30","pubTimestamp":1765233000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Perrigo Co. PLC  shed 2.68% to $13.08 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 0.35% to 6,846.51 and Dow Jones Industrial Average  falling 0.45% to 47,739.32.This was the stock's third consecutive day of losses.Perrigo Co. PLC closed 57.71% short of its 52-week high of $30.93, which the company achieved on March 3rd.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson & Johnson  fell 0.15% to $201.62, Procter & Gamble Co.  fell 3.56% to $138.34, and Abbott Laboratories  fell 2.39% to $122.09.Trading volume  eclipsed its 50-day average volume of 3.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 8, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PG","LU2750360641.GBP","LU2347655156.SGD","LU0114720955.EUR","BK4588","LU0345769128.USD","LU1057294990.SGD","LU2471134952.CNY","LU1221951129.SGD","SGXZ23171101.USD","LU2471134523.USD","LU0345770993.USD","LU0070217475.USD","LU1506573853.SGD","BK4592","IE00B19Z3B42.SGD","LU0345769631.USD","LU0061475181.USD","LU0889566641.SGD","ABT","LU1691799644.USD","LU2471134796.USD","IE00BFXG1179.USD","LU1778281490.HKD","IE00B7SZLL34.SGD","LU1061106388.HKD","LU2237957811.SGD","LU2129689605.HKD","PRGO","LU0942090050.USD","LU0098860793.USD","IE00B1XK9C88.USD","BK4568","BK4007","LU1032466523.USD","IE00B42XCP33.USD","JNJ","IE00B3PB1722.GBP","LU1732800096.USD","IE0002141913.USD","LU2237957902.USD","LU0289739699.SGD","LU2471134879.HKD","LU1066051498.USD","LU1221951046.USD","IE00B3T34201.USD","IE00BGHQF631.EUR","SG9999014575.USD","LU1280957306.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2590645813","title":"Summit Therapeutics (SMMT) Is Up 6.1% After Cancer Drug Ivonescimab Tops Keytruda Trial Results - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2590645813","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590645813?lang=en_us&edition=fundamental","pubTime":"2025-12-09 06:14","pubTimestamp":1765232073,"startTime":"0","endTime":"0","summary":"Summit Therapeutics recently reported that its experimental cancer drug ivonescimab outperformed Merck’s Keytruda in a prior clinical trial, boosting optimism about its potential. \nThis enthusiasm is tempered by concerns that limited diversity in the trial population could affect how regulators assess ivonescimab’s real-world applicability. \nWe’ll now examine how ivonescimab’s encouraging trial results, alongside lingering regulatory questions, shape Summit Therapeutics’ evolving investment...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/summit-therapeutics-smmt-is-up-61-after-cancer-drug-ivonesci","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/summit-therapeutics-smmt-is-up-61-after-cancer-drug-ivonesci","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1066053197.SGD","SG9999001440.SGD","LU1699723380.USD","LU1989772923.USD","SG9999015341.SGD","LU0266013472.USD","LU1093756325.SGD","SG9999013999.USD","LU1983299246.USD","LU1585245621.USD","LU1066051811.HKD","BK4550","LU0234572021.USD","LU1934455194.USD","IE00B1BXHZ80.USD","LU0289739699.SGD","LU2089984988.USD","LU0058720904.USD","LU2112291526.USD","LU2361044865.SGD","LU0265550946.USD","LU1116320737.USD","LU1571399168.USD","SG9999001176.USD","LU1941712348.USD","LU1037948897.HKD","IE00BBT3K403.USD","BK4585","LU2106854487.HKD","IE00BJT1NW94.SGD","IE0009355771.USD","SG9999014575.USD","LU1066051225.USD","LU1989771016.USD","SG9999002232.USD","LU0965509010.AUD","LU1057294990.SGD","LU0211331839.USD","LU1066051498.USD","LU0965509101.SGD","LU2468319806.SGD","LU1941712264.USD","LU1929549753.HKD","SG9999014542.SGD","LU1934455863.HKD","LU2023250843.SGD","LU1430594728.SGD","LU1037948541.HKD","BK4533","LU0965509283.SGD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU0985320562.USD","LU2324357040.USD","LU0122379950.USD","LU1989772840.SGD","LU0006306889.USD","LU1162221912.USD","LU0320765489.SGD","SGXZ57979304.SGD","LU0265550359.USD","LU1934455277.USD","LU0238689110.USD","LU0965508806.USD","IE000M9KFDE8.USD","IE00B2B36J28.USD","LU1116320901.HKD","BK4588","BK4534","LU0203347892.USD","LU1035773651.USD","SG9999014567.USD","IE00BN8TJ469.HKD","LU1917777945.USD","BK4516","LU0208291251.USD","LU1974910355.USD","LU2360032135.SGD","LU2461242641.AUD","SG9999001176.SGD","LU2023250504.SGD","SG9999002224.SGD","SMMT","BK4139","LU1069347547.HKD","LU0203345920.USD","IE00BLSP4452.SGD","LU0098860793.USD","LU1093756168.USD","LU2125154935.USD","LU2125154778.USD","BK4007","SG9999014559.SGD","LU0320765646.SGD","LU2361044949.HKD","LU2488822045.USD","IE00BJJMRZ35.SGD","BK4559","LU1061106388.HKD","LU2361045086.USD","IE00B4R5TH58.HKD","IE00BLSP4239.USD","LU0070302665.USD","IE00BSNM7G36.USD","IE0002141913.USD","LU0861579265.USD","LU1023059063.AUD","LU0106261372.USD","SG9999015358.SGD"],"gpt_icon":0},{"id":"2590661073","title":"Pliant Therapeutics Inc - Terminates Cmo ÉRic Lefebvre Effective December 15 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590661073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590661073?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:42","pubTimestamp":1765230176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE1BI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PLRX"],"gpt_icon":0},{"id":"2590836643","title":"Pliant Therapeutics Announces Departure of Chief Medical Officer Éric Lefebvre","url":"https://stock-news.laohu8.com/highlight/detail?id=2590836643","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590836643?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:42","pubTimestamp":1765230148,"startTime":"0","endTime":"0","summary":"Pliant Therapeutics Inc. has announced that Chief Medical Officer ric Lefebvre, M.D., will be leaving the company effective December 15, 2025. Dr. Lefebvre is expected to continue assisting the company as a consultant to support the transition of his responsibilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL7sNhWD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLRX"],"gpt_icon":0},{"id":"2590636663","title":"Protara Therapeutics Closes $75 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590636663","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590636663?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:34","pubTimestamp":1765229665,"startTime":"0","endTime":"0","summary":"Protara Therapeutics (TARA) said late Monday it has closed an underwritten public offering of about 13 million shares at $5.75 per share, for gross proceeds of roughly $75 million.Underwriters were gi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","TARA","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2590366613","title":"Abbott Laboratories Stock Underperforms Monday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590366613","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590366613?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:34","pubTimestamp":1765229640,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Abbott Laboratories  shed 2.39% to $122.09 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.35% to 6,846.51 and Dow Jones Industrial Average  falling 0.45% to 47,739.32.This was the stock's second consecutive day of losses.Abbott Laboratories closed 13.55% short of its 52-week high of $141.23, which the company achieved on March 4th.The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson  fell 0.15% to $201.62, Pfizer Inc.  fell 1.00% to $25.77, and Merck & Co. Inc.  fell 0.79% to $98.93.Trading volume  eclipsed its 50-day average volume of 6.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 8, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","SG9999011175.SGD","IE00BSNM7G36.USD","LU1732800096.USD","LU2471134796.USD","LU0058720904.USD","LU0320765646.SGD","LU2592432038.USD","LU0225771236.USD","LU2324357040.USD","LU2347655156.SGD","LU0345770993.USD","BK4592","LU0965509010.AUD","LU0792757196.USD","LU1941712264.USD","LU1116320737.USD","LU2430703251.USD","LU1430594728.SGD","IE00BGHQF631.EUR","IE00BLSP4239.USD","SG9999002224.SGD","BK4082","LU0070302665.USD","LU2471134879.HKD","LU0466842654.USD","LU1934455194.USD","LU1989772840.SGD","LU0225284248.USD","LU1061106388.HKD","LU1894683264.USD","LU2461242641.AUD","LU2361044865.SGD","LU2430703095.HKD","LU2471134523.USD","LU1989763690.USD","LU1917777945.USD","LU1974910355.USD","IE00BN8TJ469.HKD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0965509101.SGD","LU1093756168.USD","LU1093756325.SGD","LU1244550577.SGD","LU1506573853.SGD","LU1674673428.USD","LU1032466523.USD","LU1571399168.USD","LU0345769128.USD","LU0868494617.USD","LU1894683348.USD","LU2023250504.SGD","BK4585","IE00BVYPNW00.USD","LU1699723380.USD","IE00BVYPNV92.GBP","SGXZ23171101.USD","LU1244550494.USD","LU2505996509.AUD","LU0265550359.USD","LU0321505868.SGD","SGXZ57979304.SGD","LU0006306889.USD","IE0034235303.USD","LU1934455863.HKD","BK4599","LU1116320901.HKD","LU1929549753.HKD","LU2106854487.HKD","IE00B1BXHZ80.USD","LU2430703178.SGD","LU0306807586.USD","BK4566","LU2505996681.GBP","BK4559","LU1941712348.USD","LU0306806265.USD","SG9999014542.SGD","LU2112291526.USD","LU1032955483.USD","LU1732799900.SGD","BK4504","SG9999003800.SGD","ABT","LU2750360997.AUD","IE00BFXG1179.USD","LU2361044949.HKD","LU0238689110.USD","SG9999001176.SGD","LU2471134952.CNY","LU1280957306.USD","LU1057294990.SGD","BK4532","SG9999013999.USD","SGXZ41872573.SGD","SG9999015358.SGD","LU1221951046.USD","LU0170899867.USD","LU0640476718.USD","IE000M9KFDE8.USD","LU2360032135.SGD","LU1989772923.USD","LU1989771016.USD","LU2129689431.USD","LU0234570918.USD","LU2602419157.SGD","LU0795875169.SGD","IE00B3PB1722.GBP","SG9999001440.SGD","LU1066053197.SGD","LU2023250843.SGD","LU0456855351.SGD","LU2125154778.USD","IE00BZ1G4Q59.USD","LU1162221912.USD","IE00BJT1NW94.SGD","LU1934455277.USD","LU1935042991.SGD","IE0009355771.USD","LU2133065610.SGD","BK4516","LU0098860793.USD","BK4588","LU1267930813.SGD","LU1496350502.SGD","LU1585245621.USD","LU1035773651.USD","LU0882574055.USD","SG9999014567.USD","LU1291159041.SGD","LU1883839398.USD","LU1989763427.SGD","SG9999015341.SGD","LU0114720955.EUR","LU1244550221.USD","LU0203345920.USD","LU0985320562.USD","LU1037948897.HKD","LU2125154935.USD","IE00BBT3K403.USD","LU0289739699.SGD","LU2750360641.GBP","IE00BLSP4452.SGD","LU0106261372.USD","LU1718418525.SGD","LU0203347892.USD","SG9999014575.USD","LU1221951129.SGD","LU1674673691.USD","LU1074936037.SGD","LU1059921491.USD","LU1983299246.USD","LU2361045086.USD","LU2468319806.SGD","BK4533","LU1261432733.SGD","LU2211815571.USD","LU0345770308.USD","LU0985481810.HKD","IE00B7SZLL34.SGD","LU1066051225.USD","BK4568","LU0208291251.USD","LU0861579265.USD","IE00B3T34201.USD","LU0345769631.USD","SG9999001176.USD","IE0002141913.USD","LU1914381329.SGD","LU0320765489.SGD","LU2237957811.SGD","LU0321505439.SGD","LU1066051498.USD","LU0122379950.USD","LU0965508806.USD","LU0965509283.SGD","LU0912757837.SGD","LU0889566641.SGD","LU1023059063.AUD","IE00B19Z3581.USD","LU2129689605.HKD","LU2237957902.USD","LU0070217475.USD","LU0795875086.SGD","BK4550","SG9999004303.SGD","BK4581","LU0266013472.USD","LU1196500208.SGD","IE0002270589.USD","SG9999014559.SGD","LU0211331839.USD","LU1037948541.HKD","LU1066051811.HKD","IE00B42XCP33.USD","LU1721429402.USD","IE00BDGV0183.EUR","LU1778281490.HKD","LU0234572021.USD","LU1691799644.USD","LU1721429741.USD","SG9999002232.USD","LU2129689514.USD","LU0432979614.USD","LU1069347547.HKD","IE00BJJMRZ35.SGD","BK4007","LU0265550946.USD","BK4534","IE00B19Z3B42.SGD","LU2089984988.USD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2590666513","title":"Clearside Biomedical Faces Nasdaq Delisting After Bankruptcy Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590666513","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590666513?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:33","pubTimestamp":1765229605,"startTime":"0","endTime":"0","summary":"Clearside Biomedical Inc. is facing a significant regulatory issue following its voluntary Chapter 11 bankruptcy filing. As a result, the company received notice from Nasdaq that its common stock would be delisted, and trading was suspended as of December 1, 2025. Clearside subsequently filed a Form 25 with the SEC to officially remove its shares from Nasdaq and deregister them under Section 12 of the Securities Exchange Act of 1934. This move will reduce certain SEC reporting obligations for the company. The stock now trades on the OTC Pink Limited Market. No tariff-related issues were mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearside Biomedical Inc. published the original content used to generate this news brief via","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL5vsCP5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLSDQ","CLSD","BK4007"],"gpt_icon":0},{"id":"2590366583","title":"Wave Life Sciences Launches $250 Million Stock, Warrant Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590366583","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590366583?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:32","pubTimestamp":1765229548,"startTime":"0","endTime":"0","summary":"Wave Life Sciences  said late Monday it has launched a $250 million underwritten public offering of its ordinary shares, along with pre-funded warrants for select investors.The company said it plans to give underwriters a 30-day option to buy up to 15% of the shares and warrants offered on the same terms.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","WVE"],"gpt_icon":0},{"id":"2590366534","title":"AbbVie Inc. Stock Underperforms Monday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590366534","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590366534?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:31","pubTimestamp":1765229460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of AbbVie Inc.  slipped 1.31% to $223.12 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 0.35% to 6,846.51 and Dow Jones Industrial Average  falling 0.45% to 47,739.32.This was the stock's third consecutive day of losses.AbbVie Inc. closed 8.86% short of its 52-week high of $244.81, which the company reached on October 1st.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Johnson & Johnson  fell 0.15% to $201.62, Pfizer Inc.  fell 1.00% to $25.77, and Amgen Inc.  fell 2.63% to $321.23.Data source: Dow Jones Market Data, FactSet. Data compiled December 8, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","SG9999011175.SGD","LU0158827948.USD","IE00BSNM7G36.USD","LU1732800096.USD","LU2471134796.USD","LU0058720904.USD","LU0320765646.SGD","LU2592432038.USD","LU0225771236.USD","LU2347655156.SGD","LU0345770993.USD","BK4592","LU0965509010.AUD","LU0792757196.USD","LU2430703251.USD","LU1430594728.SGD","IE00BGHQF631.EUR","IE00BLSP4239.USD","SG9999002224.SGD","LU2471134879.HKD","LU0466842654.USD","LU0949170772.SGD","LU1934455194.USD","LU1989772840.SGD","LU0225284248.USD","LU1061106388.HKD","LU1894683264.USD","LU2430703095.HKD","LU2471134523.USD","LU1003077747.HKD","IE00BN8TJ469.HKD","LU0738911758.USD","IE00B4R5TH58.HKD","LU0124676726.USD","IE00B2B36J28.USD","LU0965509101.SGD","LU1093756168.USD","LU1093756325.SGD","LU1244550577.SGD","LU1506573853.SGD","LU0661504455.SGD","LU1674673428.USD","LU1032466523.USD","LU1571399168.USD","LU0345769128.USD","LU0868494617.USD","LU1894683348.USD","BK4585","IE00BVYPNW00.USD","IE00BVYPNV92.GBP","LU1244550494.USD","LU2505996509.AUD","LU0321505868.SGD","LU2089283258.USD","LU2237443465.HKD","IE0004445239.USD","SGXZ57979304.SGD","IE0034235303.USD","LU1934455863.HKD","BK4599","LU1929549753.HKD","LU2430703178.SGD","IE00B1BXHZ80.USD","LU0306807586.USD","LU1839511570.USD","BK4566","LU1496350171.SGD","LU2505996681.GBP","LU0820561818.USD","BK4559","BK4139","LU0306806265.USD","LU2112291526.USD","ABBV","LU1032955483.USD","LU1732799900.SGD","BK4504","SG9999003800.SGD","LU2750360997.AUD","LU0708994859.HKD","IE00BFXG1179.USD","SG9999001176.SGD","LU2471134952.CNY","LU1280957306.USD","LU1057294990.SGD","BK4532","SG9999013999.USD","LU1221951046.USD","LU0170899867.USD","LU0640476718.USD","IE000M9KFDE8.USD","LU1989772923.USD","LU0310799852.SGD","LU1989771016.USD","LU2129689431.USD","LU0234570918.USD","LU2602419157.SGD","LU0795875169.SGD","IE00B3PB1722.GBP","SG9999001440.SGD","LU1066053197.SGD","SG9999015945.SGD","LU0456855351.SGD","IE00BZ1G4Q59.USD","LU0211328371.USD","LU1162221912.USD","IE00BJT1NW94.SGD","LU1934455277.USD","LU1935042991.SGD","IE0009355771.USD","LU2133065610.SGD","LU0098860793.USD","BK4588","LU0256863811.USD","LU1267930813.SGD","LU1496350502.SGD","LU1585245621.USD","SG9999015986.USD","LU0882574055.USD","LU0128525929.USD","LU0211327993.USD","LU1291159041.SGD","LU0109394709.USD","LU1883839398.USD","LU2237443382.USD","LU0114720955.EUR","LU1244550221.USD","LU2087621335.USD","LU0417517546.SGD","LU1267930490.SGD","LU0203345920.USD","LU0985320562.USD","LU1037948897.HKD","LU0943347566.SGD","LU1551013342.USD","LU2237443895.HKD","IE00BBT3K403.USD","LU0256863902.USD","LU0289739699.SGD","IE00BLSP4452.SGD","LU0689472784.USD","LU1718418525.SGD","LU2023251221.USD","LU0203347892.USD","LU2750360641.GBP","LU1221951129.SGD","LU1674673691.USD","LU1074936037.SGD","LU1059921491.USD","LU1983299246.USD","SG9999015952.SGD","LU2468319806.SGD","BK4533","LU1261432733.SGD","LU0345770308.USD","LU0985481810.HKD","IE00B7SZLL34.SGD","LU1066051225.USD","LU0553294199.USD","BK4568","LU0310800379.SGD","LU0889565916.HKD","LU2242646821.SGD","LU0861579265.USD","LU2237443622.USD","IE00B3T34201.USD","LU0320765992.SGD","LU0345769631.USD","SG9999001176.USD","IE0002141913.USD","LU1914381329.SGD","LU0820561909.HKD","LU0321505439.SGD","LU1066051498.USD","LU1267930573.SGD","LU0122379950.USD","LU0965508806.USD","LU0965509283.SGD","LU0912757837.SGD","LU0889566641.SGD","LU1023059063.AUD","IE00B19Z3581.USD","LU2129689605.HKD","LU0070217475.USD","LU2242652126.USD","LU0795875086.SGD","BK4550","BK4581","LU1196500208.SGD","LU2237443549.SGD","IE0002270589.USD","LU2237443978.SGD","SG9999015978.USD","LU0545039389.USD","LU1037948541.HKD","LU1551013425.SGD","LU0689626769.HKD","LU1066051811.HKD","IE00B42XCP33.USD","IE00BDGV0183.EUR","LU1778281490.HKD","LU0029864427.USD","LU0234572021.USD","SG9999002232.USD","LU2129689514.USD","LU0432979614.USD","LU0198837287.USD","IE00BJJMRZ35.SGD","BK4007","LU2089284900.SGD","BK4534","IE00B19Z3B42.SGD","LU2089984988.USD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2590392366","title":"Bristol Myers Squibb Unveils Promising Lymphoma Therapy Data at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590392366","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590392366?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229456,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb has announced new research advances in lymphoma at the upcoming 67th American Society of Hematology  Annual Meeting. The company will present updates from its targeted protein degradation pipeline, including data on the investigational CELMoD agent golcadomide and the BCL6 ligand-directed degrader BMS-986458. Additionally, long-term results for Breyanzi , a CD19-directed CAR T cell therapy, will be shared from the Phase 3 TRANSFORM and Phase 2 TRANSCEND FL trials. These presentations reinforce Bristol Myers Squibb's ongoing commitment to hematology research and cancer care.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLJVDQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU2125154935.USD","LU1585245621.USD","LU0321505439.SGD","LU0237698245.USD","BK4007","BK4559","LU1670710588.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0225284248.USD","LU0882574055.USD","IE0009355771.USD","LU1291159041.SGD","LU1718418525.SGD","LU1261432733.SGD","BK4588","IE00B2B36J28.USD","LU1868837300.USD","LU1093756168.USD","LU1032466523.USD","BK4532","LU0225771236.USD","IE00BFXG1179.USD","LU1430594728.SGD","LU0306806265.USD","LU0985481810.HKD","LU1670710661.SGD","LU1868836914.USD","LU0096364046.USD","LU2242646821.SGD","LU1074936037.SGD","LU1670711123.USD","LU1571399168.USD","LU1989771016.USD","LU1093756325.SGD","LU0114720955.EUR","LU1868836591.USD","LU1323610961.USD","LU1670711040.USD","LU0306807586.USD","LU0456855351.SGD","BMY","LU0061475181.USD","LU0868494617.USD","LU2242652126.USD","LU1868837136.USD","LU0267386448.USD","LU0321505868.SGD","BK4581"],"gpt_icon":0},{"id":"2590136632","title":"ADRs Advance; Structure Therapeutics Inc. Climbs 102%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590136632","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590136632?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:30","pubTimestamp":1765229400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Monday, as the S&P/BNY Mellon index of American depositary receipts increased 0.2% to 232.70.The European index dropped 0.1% to 204.60. The Asian index increased 0.4% to 311.92. The Latin American index added 0.5% to 236.03, while the emerging-markets index rose 1.0% to 523.49.United States's Structure Therapeutics Inc. was the biggest leader during the session, rocketing 102% to $69.98, and United Kingdom-based Biodexa Pharmaceuticals PLC rocketed 75% to $8.80. Immutep Ltd., which is based in Australia, rounded out the top three leaders on Monday, with shares rocketing 26% to $2.27.Mobilicom Ltd., based in Australia, posted the largest decline, plunging 15% to $6.77, followed by shares of China's Adlai Nortye Ltd., which tumbled 13% to 88 cents. Shares of China-based 51Talk Online Education Group plunged 12% to $36.21.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2590365052","title":"U.S. Small Caps Close Mixed As WAVE Life Sciences Leads, New Found Gold Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365052?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:20","pubTimestamp":1765228800,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies were mixed Monday, as the Russell 2000 Index closed flat, and the S&P Small Cap 600 Index was down 0.4%.Among companies with a market value of $1 billion to $6.7 billion, WAVE Life Sciences Ltd. was the best performer during the session, surging 147%, followed by Kymera Therapeutics Inc., which surged 41%. Terns Pharmaceuticals Inc. shares surged 37%, Ocular Therapeutix Inc. jumped 28%, and shares of Nurix Therapeutics Inc. surged 19%.New Found Gold Corp. was the biggest laggard, dropping 11%, followed by shares of Omada Health Inc., which dropped 11%. Shares of Sana Biotechnology Inc. dropped 9.7%, Acadia Healthcare Co. Inc. shares tumbled 9.5%, and American Bitcoin Corp. tumbled 9.4%.Major U.S. stock indexes declined Monday as the Nasdaq Composite Index fell 0.1%. Meanwhile, the S&P 500 Index fell 0.3%, and the Dow Jones Industrial Average dropped 0.4%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WAVE","BK4133","BK4007","BK4539"],"gpt_icon":1},{"id":"2590365280","title":"Structure Therapeutics Plans $500 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365280","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365280?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:15","pubTimestamp":1765228520,"startTime":"0","endTime":"0","summary":"Structure Therapeutics  said late Monday it plans a public offering of $500 million of American Depositary shares.The company said it plans to grant its underwriters a 30-day option to buy up to an additional $75 million of depository shares.Investors can also buy pre-funded warrants in lieu, it added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","LENZ","BK4599","GPCR","BK4007"],"gpt_icon":0},{"id":"2590652553","title":"Jaguar Health Inc. Held Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2590652553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590652553?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:15","pubTimestamp":1765228514,"startTime":"0","endTime":"0","summary":"Jaguar Health Inc. held a Special Meeting of Stockholders on December 8, 2025. Three proposals were submitted to stockholders and all were approved at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL4h6hrS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","JAGX"],"gpt_icon":0},{"id":"2590769364","title":"Elanco Animal Health (ELAN): Reassessing Valuation After a 70% One-Year Share Price Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2590769364","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590769364?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:11","pubTimestamp":1765228274,"startTime":"0","endTime":"0","summary":"Elanco Animal Health (ELAN) has quietly turned into a strong comeback story, with shares up roughly 70% over the past year as improving earnings and steady revenue growth reset expectations around its long term potential.\nSee our latest analysis for Elanco Animal Health.\nThe latest $21.9 share price sits on top of an 81.74% year to date share price return and a 70.03% total shareholder return over the past year, signalling that investors are steadily repricing Elanco for renewed growth rather...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-animal-health-elan-reassessing-valuation-after-a-70-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/elanco-animal-health-elan-reassessing-valuation-after-a-70-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4561","BK4007","LU1941712264.USD","LU1941712348.USD","ELAN"],"gpt_icon":0},{"id":"2590365105","title":"Eli Lilly Files Initial Beneficial Ownership Statement for Director Carolyn R. Bertozzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365105","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365105?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:11","pubTimestamp":1765228261,"startTime":"0","endTime":"0","summary":"Eli Lilly and Company has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Carolyn R. Bertozzi as the beneficial owner in her role as Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL16kbd8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014914.USD","SGXZ99366536.SGD","LU0432979614.USD","LU2552382215.SGD","LU1814569148.SGD","LU0256863811.USD","BK4585","SGXZ31699556.SGD","LU0106261372.USD","IE00BFSS7M15.SGD","LU0096364046.USD","LU2456880835.USD","SG9999014880.SGD","SG9999014906.USD","LU0456855351.SGD","LU2491050071.SGD","SG9999015952.SGD","IE00B1XK9C88.USD","LU1127390331.HKD","LU2106854487.HKD","IE00BFSS8Q28.SGD","LU2236285917.USD","LU2237443465.HKD","LU2237443382.USD","SG9999001176.USD","LU0820561818.USD","LU0353189680.USD","IE00BFTCPJ56.SGD","LU2471134879.HKD","LU1035775433.USD","LU2491050154.USD","LU0385154629.USD","LU2168564222.USD","LU0471298694.HKD","LU1974910355.USD","LU2087625088.SGD","IE00BK4W5L77.USD","LU0198837287.USD","SG9999017495.SGD","LU0109391861.USD","LU2471134796.USD","LU0354030438.USD","LU0354030511.USD","LU2265009873.SGD","LU1868836591.USD","LU1057294990.SGD","LU1551013425.SGD","LU2168564149.EUR","LU2471134952.CNY","LU1069344957.HKD","BK4588","LU0114720955.EUR","LU0256863902.USD","LU0823416689.USD","LU1551013342.USD","LU0203201768.USD","LU2471134523.USD","LU2750360641.GBP","LU1267930730.SGD","LU0708995401.HKD","LU1023059063.AUD","LU0006306889.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","IE00BJJMRZ35.SGD","SGXZ51526630.SGD","LU2750360997.AUD","IE00BKDWB100.SGD","LU1983299246.USD","LU2361045086.USD","LU1093756168.USD","LU2237443895.HKD","LU2746668461.USD","IE00B1BXHZ80.USD","LU0316494557.USD","LU1366192091.USD","BK4007","LU1291159041.SGD","LU0786609619.USD","LU1712237335.SGD","LU0320765059.SGD","LU0238689110.USD","LU2361044865.SGD","LU0109394709.USD","IE0004445015.USD","SGXZ57979304.SGD","LU2063271972.USD","LU1232071149.USD","LU0640476718.USD","LU1989771016.USD","LU1868836914.USD","LU1093756325.SGD","LU1868837300.USD","LU2108987350.USD","LU0094547139.USD","LU1988902786.USD","LU2168564065.EUR","BK4599","IE0005OL40V9.USD","LU2461242641.AUD","IE00BWXC8680.SGD","LU0672654240.SGD","LU2491049909.HKD","LU1917777945.USD","LU1720051108.HKD","LU2552382132.HKD","LU0943347566.SGD","LU0058720904.USD","LU2417539215.USD","SG9999015986.USD","LU2360106947.USD","SG9999018865.SGD","IE00B7KXQ091.USD","LU0234572021.USD","LU1720051017.SGD","LU0882574139.USD","SG9999013999.USD","IE0002141913.USD","LU2168564495.EUR","LU2264538146.SGD","LU2602419157.SGD","LU2552382058.USD","SG9999015945.SGD","BK4533","LU1548497426.USD","IE00B2B36J28.USD","LU2468319806.SGD","SG9999001176.SGD","LU0889565916.HKD","LU1623119135.USD","LU0466842654.USD","LU0823434583.USD","IE00B4JS1V06.HKD","LU1804176565.USD","SG9999015978.USD","LU2211815571.USD","LLY","IE00BN29S564.USD","LU2089984988.USD","LU0689472784.USD","SGXZ81514606.USD","LU0320765992.SGD","LU0203202063.USD","LU0471298777.SGD","LU0079474960.USD","LU1868836757.USD","LU2237443549.SGD","LU2237438978.USD","LU0820561909.HKD","LU2237443978.SGD","BK4581","BK4516","LU1280957306.USD","LU1061106388.HKD","LU2023250504.SGD","SG9999014898.SGD","LU2462157665.USD","IE00BJJMRY28.SGD","LU0353189763.USD","LU2112291526.USD","IE0004445239.USD","LU1868837136.USD","LU0122379950.USD","SG9999018857.SGD","LU2361044949.HKD","LU2746668974.SGD","LU0882574055.USD","IE00BJJMRX11.SGD","LU0061475181.USD","BK4534","IE00BJLML261.HKD","LU0266013472.USD","LU1323610961.USD","LU2357305700.SGD","LU0823434740.USD","LU0323591593.USD","GB00BDT5M118.USD","IE00BK4W5M84.HKD","LU2324357040.USD","LU0097036916.USD","LU0417517546.SGD","IE0009355771.USD","LU1064131342.USD","IE00B4R5TH58.HKD","IE00B775H168.HKD","LU2237443622.USD","IE00BKPKM429.USD","LU2168563687.JPY"],"gpt_icon":1}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4007","nameEN":"BK4007"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharmacy(BK4007),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharmacy(BK4007) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharmacy,BK4007,Pharmacy股票,Pharmacy股票老虎,Pharmacy股票老虎国际,Pharmacy行情,Pharmacy股票行情,Pharmacy股价,Pharmacy股市,Pharmacy股票价格,Pharmacy股票交易,Pharmacy股票购买,Pharmacy股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharmacy(BK4007),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharmacy(BK4007) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}